Edit

Lypro Biosciences Inc.

http://www.cerenis.com/
Tags:DeliveryDevelopmentDrugSpace
November 8, 2017 Toulouse, FRANCE, Lakeland, UNITED STATES, CERENIS Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, today announces the acquisition of LYPRO Biosciences assets, a portfolio of proprietary drug delivery nanotechnology. The operation positions CERENIS at the forefront of the chemotherapy drug delivery and immuno-oncology space. This represents a significant step towards the Company’sstrategic objective of developing the next generation of multiple targeted drug delivery nanotechnologies associated with HDL therapy.
Location: United States, California, Berkeley
Member count: 11-50
Total raised: $65.870402M
Founded date: 2005

Investors 1

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
21.10.2010Series C$13.955253...-finsmes.co...
26.07.2010Series C$51.915149...-finsmes.co...

Mentions in press and media 41

DateTitleDescriptionCategoryAuthorSource
23.08.2011Venture Fi...Share Share on Facebook Share ...-Sarah Schm...xconomy.co...
22.10.2010Cerenis Th...The company has several choles...--medcitynew...
21.10.2010Cerenis Th...Cerenis Therapeutics, a biopha...France fu...-finsmes.co...
26.07.2010Cerenis Th...Promoted This Patient Experie...--medcitynew...
26.07.2010Cerenis Th...Cerenis Therapeutics SA, a Tou...France fu...-finsmes.co...
-CERENIS Th...• Combining LYPRO Biosciences’...--healthcap....
-CER-001: A...Toulouse, FRANCE, Ann Arbor, U...--healthcap....
-Positive s...Professor Alberto Corsini, Dep...--healthcap....
-New Data f...Data show that CER-001 at 3 mg...--healthcap....
-Cerenis Re...TOULOUSE, France and ANN ARBOR...--healthcap....
Show more